Citryll Announces the Appointment of Paul Peter Tak as Chair of the Board of Directors
Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat autoimmune and autoinflammatory diseases, today announced that Dr. Paul Peter Tak, Citryll Board member since
Source: finanznachrichten.de